Jarislowsky Fraser Ltd raised its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 6.1% during the first quarter, Holdings Channel reports. The firm owned 2,068 shares of the medical instruments supplier’s stock after buying an additional 118 shares during the period. Jarislowsky Fraser Ltd’s holdings in C.R. Bard were worth $513,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of BCR. Keybank National Association OH increased its position in C.R. Bard by 0.3% in the fourth quarter. Keybank National Association OH now owns 4,353 shares of the medical instruments supplier’s stock worth $978,000 after buying an additional 13 shares during the period. ETRADE Capital Management LLC increased its position in C.R. Bard by 1.7% in the third quarter. ETRADE Capital Management LLC now owns 1,054 shares of the medical instruments supplier’s stock worth $236,000 after buying an additional 18 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in C.R. Bard by 0.5% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,215 shares of the medical instruments supplier’s stock worth $947,000 after buying an additional 20 shares during the period. Burns J W & Co. Inc. NY increased its position in C.R. Bard by 1.3% in the first quarter. Burns J W & Co. Inc. NY now owns 1,581 shares of the medical instruments supplier’s stock worth $393,000 after buying an additional 21 shares during the period. Finally, Creative Planning increased its position in C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock worth $1,068,000 after buying an additional 29 shares during the period. 88.32% of the stock is currently owned by institutional investors and hedge funds.
C.R. Bard, Inc. (NYSE BCR) traded down 0.12% during mid-day trading on Friday, reaching $313.56. 728,015 shares of the company were exchanged. The firm has a market capitalization of $22.71 billion, a P/E ratio of 39.91 and a beta of 0.64. The stock has a 50-day moving average of $309.48 and a 200 day moving average of $257.26. C.R. Bard, Inc. has a 1-year low of $203.63 and a 1-year high of $315.29.
C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.65 by $0.22. C.R. Bard had a return on equity of 48.72% and a net margin of 15.70%. The firm had revenue of $938.80 million during the quarter, compared to the consensus estimate of $916.15 million. During the same period last year, the company earned $2.34 earnings per share. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Equities research analysts forecast that C.R. Bard, Inc. will post $11.78 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, August 4th. Investors of record on Monday, July 24th will be issued a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a dividend yield of 0.33%. The ex-dividend date of this dividend is Thursday, July 20th. C.R. Bard’s dividend payout ratio is presently 13.21%.
ILLEGAL ACTIVITY WARNING: “Jarislowsky Fraser Ltd Boosts Position in C.R. Bard, Inc. (BCR)” was first published by WKRB News and is the property of of WKRB News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.wkrb13.com/markets/2230280/jarislowsky-fraser-ltd-boosts-position-in-c-r-bard-inc-bcr.html.
A number of research analysts have commented on the stock. BMO Capital Markets downgraded shares of C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 target price on the stock. in a research report on Tuesday, April 25th. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective on the stock in a research report on Tuesday. Morgan Stanley downgraded shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research report on Monday, April 24th. Cowen and Company lifted their price objective on shares of C.R. Bard from $240.00 to $317.00 and gave the stock a “market perform” rating in a research report on Monday, April 24th. Finally, Jefferies Group LLC lifted their price objective on shares of C.R. Bard from $237.00 to $317.00 and gave the stock a “hold” rating in a research report on Monday, April 24th. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. C.R. Bard currently has an average rating of “Hold” and an average target price of $265.62.
In related news, VP Frank Lupisella, Jr. sold 3,622 shares of the stock in a transaction on Monday, April 24th. The stock was sold at an average price of $304.00, for a total transaction of $1,101,088.00. Following the completion of the sale, the vice president now directly owns 10,139 shares of the company’s stock, valued at $3,082,256. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.80% of the stock is owned by company insiders.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230280/jarislowsky-fraser-ltd-boosts-position-in-c-r-bard-inc-bcr.html
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.